Drug shortages continue to put patients at risk.

As highlighted by The National Desk’s Spotlight on America, children with cancer and their families continue to face uncertainty when critical medicines like ifosfamide are in short supply.

For Abby Bray, this was personal. Patient One was Abby. Her experience navigating drug shortages during cancer treatment became the catalyst for Laura Bray’s advocacy and the founding of Angels for Change.

We remain committed to advancing solutions that strengthen the pharmaceutical supply chain and ensure every patient has access to the medicines they need.

Women across the country are struggling to access estrogen patches, with some traveling long distances, rationing medication, or searching for alternatives to maintain access to their treatment.

The New York Post recently examined the shortage and the challenges patients are facing. Laura Bray, Founder of Angels for Change, spoke with the publication about why the shortage was predictable following the FDA’s removal of the black box warning for estrogen-based hormone replacement therapy.

For the first time since 2019, Abby Bray is sharing her cancer journey in her own words.

For years, Abby kept her story private. Now, five years cancer-free, she is choosing to share her experience and use her voice to advocate for other patients facing drug shortages.

Abby was Patient One for Angels for Change.

Today, she is helping carry that mission forward as a member of the Angels for Change Patient Advocacy Board, which brings patients, caregivers, and lived experiences directly into our advocacy work.

Drug shortages continue to put patients at risk, threatening access to lifesaving cancer treatments and creating uncertainty for healthcare providers who are often forced to make urgent, real-time decisions about patient care.

The 2025 USP Drug Shortages Report has been released, and it highlights a troubling trend: discontinuations of essential, life-saving medicines continue to rise.

In 2025, drug product discontinuations increased by 60%, reaching the highest annual total in 5 years. Drug shortages are often driven by single points of failure; medicines that are manufactured at only one facility or place in the world. When products are discontinued, the market becomes even more concentrated, leaving patients with fewer treatment options and fewer backup sources when disruptions occur.

In a recent interview with Healthcare Brew, Laura Bray discussed how the Iran war could create new vulnerabilities across the global pharmaceutical supply chain, adding pressure to a system already struggling with ongoing drug shortages.

Laura Bray and Angels for Change highlighted in the newly released white paper from the API Innovation Center, “Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain.”

Bray emphasized a clear call to action for leaders across the healthcare ecosystem to work together to solve the drug shortage crisis:

“This is not the patient’s job to solve at all… This is a supply chain failure.”

Nearly half of U.S. drug shortages, 47%, are tied to sudden spikes in demand, according to new data from the USP Medicine Supply Map. Angels for Change Project GOLD is highlighted in the article as a solution-oriented initiative that uses demand signals and buffer supply to help protect patients from shortages.